SQZ Biotechnologies (NYSE:SQZ) receives an average Buy rating from analysts

0

SQZ Biotechnologies (NYSE:SQZ – Get Rating) stock has been given an average rating of “Buy” by the two research firms currently covering the company, reports MarketBeat. Two research analysts have given the stock a buy rating. The average 1-year target price set by analysts covering the stock over the last year is $28.50.

Separately, Chardan Capital took over coverage of SQZ Biotechnologies in a report Wednesday, May 25. They put a “buy” rating on the company and a price target of $17.00.

Shares of the NYSE SQZ fell $0.35 on Friday midday to hit $3.54. 81,352 shares of the company were traded compared to an average volume of 323,003. SQZ Biotechnologies has a 1 year low of $2.73 and a 1 year high of $16.17. The stock has a market cap of $99.64 million, a price-to-earnings ratio of -1.34 and a beta of 3.71. The company has a 50-day moving average of $3.67 and a 200-day moving average of $6.28.

SQZ Biotechnologies (NYSE:SQZ – Get Rating) last announced earnings results on Tuesday, May 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%. As a group, equity analysts expect SQZ Biotechnologies to post -2.87 EPS for the current fiscal year.

In other news from SQZ Biotechnologies, Director Klavs F. Jensen acquired 14,326 shares of SQZ Biotechnologies in a transaction that took place on Wednesday, May 25th. The stock was purchased at an average price of $3.52 per share for a total value of $50,427.52. Following the purchase, the director now owns 353,309 shares of the company, valued at $1,243,647.68. The transaction was disclosed in a document filed with the SEC, available at this hyperlink. 18.00% of the shares are currently owned by company insiders.

A number of hedge funds recently changed their holdings in the company. Charles Schwab Investment Management Inc. increased its position in SQZ Biotechnologies by 7.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 60,693 shares of the company’s stock valued at $292,000 after purchasing an additional 4,196 shares last quarter. NanoDimension Inc. acquired a new position in SQZ Biotechnologies stock valued at approximately $12,906,000 during the fourth quarter. BlackRock Inc. increased its holdings in SQZ Biotechnologies stock by 13.1% during the fourth quarter. BlackRock Inc. now owns 1,413,870 shares of the company’s stock valued at $12,625,000 after purchasing an additional 163,780 shares last quarter. Goldman Sachs Group Inc. increased its stake in SQZ Biotechnologies by 24.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 43,439 shares of the company’s stock valued at $388,000 after purchasing an additional 8,449 shares last quarter. Finally, during the fourth quarter, Virtu Financial LLC acquired a new position in SQZ Biotechnologies stock valued at approximately $112,000. 66.56% of the shares are currently owned by institutional investors.

SQZ Biotechnologies company profile (received rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, is developing cell therapies for patients suffering from cancer, autoimmune diseases, infectious diseases and other serious diseases. Its lead product candidate is SQZ-PBMC-HPV from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical , head and neck, anal, penile, vulva and vaginal cancer.

Selected Stories



Receive News & Reviews for SQZ Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SQZ Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

Comments are closed.